Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

Prostate Cancer Clinical Trial

— PSMA SBRT-SIB  

Official title:

Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04402151
• Other study ID #: 19-10020928
• Secondary ID: R01CA249615
• Status: Recruiting
• Phase: Phase 2
• Start date: June 30, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: March 2024
• Source: Weill Medical College of Cornell University
• Contact: Sharanya Chandrasekhar, M.S.
• Phone: 646-962-2196
• Email: shc2043[@]med.cornell.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.

Description:

Localized prostate cancer can be treated in 5 sessions using a precise, targeted form of radiation known as stereotactic body radiation therapy (SBRT), with low toxicity. Despite these advances, overall outcomes for aggressive (high risk) prostate cancer remain poor, with 10-year recurrence-free survival of approximately 65% regardless of treatment modality. Recurrences are typically distant and carry poor prognosis, with 5 year survival of 25%. The investigators propose to utilize the latest advances in cancer imaging (PSMA Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MR)) and radiation delivery (MR-guided radiation therapy with real-time adaptive planning), to deliver a personalized radiation treatment that targets the areas of greatest risk of recurrence in the prostate with improved precision, and as a result improve clinical outcomes for individuals with high risk prostate cancer. PSMA PET/MR is a novel imaging modality, not yet widely available, that augments the tissue detail provided by MR. The combination of PSMA PET with MR results in improved delineation of intraprostatic nodules and higher diagnostic accuracy for detection of metastatic disease compared to conventional imaging. PSMA PET/MR imaging data is readily transferable to a MR-based linear accelerator (MR-LINAC), a novel, innovative platform that allows direct visualization of the tumor during treatment, and permits real-time individualized correction for motion with online adaptive radiation planning.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 21 Years to 90 Years

Eligibility

Inclusion Criteria:

• Male aged 21 years or older.
• Ability to provide signed informed consent and willingness to comply with protocol requirements.
• Pathologic confirmation of high-risk adenocarcinoma of the prostate gland as follows:

a. Gleason 8-10 or tertiary component 5 disease and/or b. PSA of 20 ng/ml or greater and/or c. Tumor stage of T2c or greater; OR Unfavorable intermediate risk (Gleason 4+3=7, >50% of cores involved, or 2 or more intermediate risk factors which include Gleason 7 disease, PSA 10-20, or T2b disease)

• Participants must agree to use an acceptable form of birth control and utilize condoms for a period of seven days after each PSMA injection, if engaged in sexual activity.
• No evidence of metastatic disease, including pelvic lymph nodes.

Exclusion Criteria:

• Clinical and/or technical factors that would compromise statistical analysis of the PET and/or MR.
• Contraindications to PSMA IV administration
• Contraindications to prostate SBRT (history of transurethral resection of prostate; prostate size greater than 150 cc; AUA score greater than 20; history of prior radiation to the prostate)
• Other unspecified reasons that, in the opinion of investigators, make the subject unsuitable for enrollment
• Patients on or intending to take abiraterone will be excluded

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired. Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage. The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT).

Radiation:
• Stereotactic Body Radiation Therapy (SBRT)
Patients will receive standard of care radiation therapy (SBRT)

Locations

Country	Name	City	State
United States	Weill Cornell Medicine	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical efficacy of prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR), MR-Linear Accelerator (LINAC) will be assessed by evaluating recurrence free survival	Evaluate the clinical efficacy of PSMA PET/MR guided, MR-LINAC-based SBRT- SIB in high-intermediate and high risk prostate cancer, as evaluated by the 2-year recurrence-free survival rate	24 months
Secondary	Performance of PSMA PET/MR to MR alone at staging prostate cancer	Detection of metastatic disease on each scan will be recorded, with pathologic confirmation obtained. Detection of intraprostatic nodules will be recorded with pathologic confirmation obtained.	Baseline
Secondary	Performance of PSMA PET/MR to MR alone for identification of dominant intraprostatic nodules during radiation planning	The Dominant Intraprostatic Nodules (DIN) will be defined with radiologist assistance on MR alone, and subsequently PSMA PET/MR. The incidence of alterations in target will be recorded.	Baseline
Secondary	Compare imaging biomarkers of interest on MR and PSMA PET/MR as predictors of treatment response, versus biopsy of treatment response and PSA		Baseline
Secondary	Compare imaging biomarkers of interest on MR and PSMA PET/MR as predictors of treatment response, versus biopsy of treatment response and PSA		12 months
Secondary	Change in Quality of life questionnaires (EPIC-26) will be assessed.	Expanded Prostate Cancer Index Composite (EPIC) short form questionnaire. The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Scores range from 0 to 100, lower scores indicate worse outcomes and higher EPIC scores represent better outcomes.	Baseline, 1month, 6months, 12 months, 18 months and 24 months.
Secondary	Change in The American Urological Association (AUA) symptom score	The American Urological Association (AUA) has created this symptom index for understanding the severity of enlarged prostate symptoms. Scores ranging from 0-7 are considered to be mild symptoms, 8-19 are moderate and 20 - 35 are severe symptoms.	Baseline, 1month, 6months, 12 months, 18 months and 24 months.
Secondary	Change in Number of Subjects with Adverse events	Adverse events will be collected from patients based on CTCAE version 5.0.	Baseline, 1month, 6months, 12 months and 24 months.
Secondary	The change in radiation doses received by the surrounding normal structures/PTV for each initial and adapted plan will be analyzed with a signed-rank Wilcoxon test (non-parametric test for paired comparisons).	PTV is the planning target volume	Baseline, 1month
Secondary	Compare the changes in the Microbiome during SBRT-SIB	Gut microbiome samples will be obtained for 16S RNA analyses	Baseline
Secondary	Compare the changes in the Microbiome during SBRT-SIB	Gut microbiome samples will be obtained for 16S RNA analyses	approx. 3 weeks
Secondary	Compare the changes in the Microbiome during SBRT-SIB	Gut microbiome samples will be obtained for 16S RNA analyses	12 months
Secondary	Compare the immunological changes during SBRT-SIB	serum samples will be obtained for immune correlate analyses	Baseline
Secondary	Compare the immunological changes during SBRT-SIB	serum samples will be obtained for immune correlate analyses	approx. 3 weeks
Secondary	Compare the immunological changes during SBRT-SIB	serum samples will be obtained for immune correlate analyses	12 months